Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholde... ( Treasury stock ...)

Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting

Date:11/8/2007

Treasury stock (5,321) (5,321)

Accumulated deficit (248,347) (216,668)

Total stockholders' equity 83,150 111,388

Total liabilities and stockholders' equity $223,854 $265,877

Nabi Biopharmaceuticals

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share amounts)

For the Three Months Ended For the Nine Months Ended

September 29, September 30, September 29, September 30,

2007 2006 2007 2006

Revenues $20,110 $ 19,634 $ 64,731 $59,525

Cost of products

sold 14,694 15,428 41,181 44,310

Gross margin 5,416 4,206 23,550 15,215

Selling, general and

administrative

expense 8,915 10,366 27,503 33,365

Research and

development expense 12,932 10,240 32,035 27,901

Operating loss (16,431) (16,400) (35,988) (46,051)

Interest income 1,444 908 4,443 2,916

Interest expense (923) (937) (2,727) (2,796)

Other income

(expense), net 9 (54) 2,569 329

Loss from continuing

operations before

income taxes (15,901) (16,483) (31,703) (45,602)

Income taxes - 162 (190) 162

Loss from continuing

operations (15,901) (16,321) (31,893) (45,440)

Net income (loss)

from discontinued

operations 27 (5,4
'/>"/>

Post Your Comments:

Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholde...( Treasury stock ...),Health